Thrombosis associated with procainamide-induced lupus anticoagulant.
A predisposition to thrombosis in patients with procainamide-induced lupus anticoagulants is previously unrecognized. We describe two patients treated with procainamide who experienced acute thromboembolic events temporally associated with development of the lupus anticoagulant. One patient had a deep venous thrombosis and pulmonary embolism, while the other patient had a cerebrovascular accident. In both patients, coagulation parameters corrected with interruption of procainamide therapy. We suggest that thrombosis may complicate treatment with procainamide in patients who develop the lupus anticoagulant.
List
A F
AF
Department of Medicine, Veterans Administration Medical Center, Phoenix, Ariz.
Doll
D C
DC
D000368:Aged; D001327:Autoimmune Diseases / Q000097:blood / Q000209:etiology; D001779:Blood Coagulation Factors / Q000276:immunology* / Q000502:physiology; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D008297:Male; D008875:Middle Aged; D011342:Procainamide / Q000009:adverse effects*; D011655:Pulmonary Embolism / Q000097:blood / Q000209:etiology; D013923:Thromboembolism / Q000097:blood / Q000209:etiology; D013924:Thrombophlebitis / Q000097:blood / Q000209:etiology; D013927:Thrombosis / Q000097:blood / Q000209:etiology*
D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor; D011342:Procainamide